FUNDING This work was supported by a grant (Eun Young Lee, 2016F-3 and 2020F-3) from the Korean Diabetes Association
Its these real-world outcomesnot just clinical studiesthat highlight the impact of making semaglutide treatment accessible, especially for those previously left out of the conversation
Half-life: roughly 30 minutes Dosing: typically once or twice daily, often at bedtime Effect: a strong, clean pulse of GH that resolves within hours, preserving most of the natural pulsatile rhythm Without DAC, the peptide doesnt anchor to albumin, so it clears quickly
BPC-157 is listed under S0 (Non-Approved Substances)
If efficacy and clinical backing matter most, injectable tirzepatide is the strongest option
If you experience any unpleasant side effects, please talk to your doctor about further treatment